AI Article Synopsis

  • Immune-mediated inflammatory diseases (IMIDs) are diverse, chronic conditions caused by an abnormal immune response that can affect various organs, resulting in serious health issues and a lower quality of life for patients.
  • Currently, there are no reliable biomarkers to predict disease progression or treatment response, making it difficult to effectively manage these conditions for many patients.
  • The ImmUniverse consortium, consisting of 27 partners, aims to improve understanding of IMIDs like ulcerative colitis and atopic dermatitis by utilizing a multi-omics approach to identify new biomarkers, which would help tailor treatments to individual patient needs and move toward personalized medicine.

Article Abstract

Immune mediated inflammatory diseases (IMIDs) are a heterogeneous group of debilitating, multifactorial and unrelated conditions featured by a dysregulated immune response leading to destructive chronic inflammation. The immune dysregulation can affect various organ systems: gut (e.g., inflammatory bowel disease), joints (e.g., rheumatoid arthritis), skin (e.g., psoriasis, atopic dermatitis), resulting in significant morbidity, reduced quality of life, increased risk for comorbidities, and premature death. As there are no reliable disease progression and therapy response biomarkers currently available, it is very hard to predict how the disease will develop and which treatments will be effective in a given patient. In addition, a considerable proportion of patients do not respond sufficiently to the treatment. ImmUniverse is a large collaborative consortium of 27 partners funded by the Innovative Medicine Initiative (IMI), which is sponsored by the European Union (Horizon 2020) and in-kind contributions of participating pharmaceutical companies within the European Federation of Pharmaceutical Industries and Associations (EFPIA). ImmUniverse aims to advance our understanding of the molecular mechanisms underlying two immune-mediated diseases, ulcerative colitis (UC) and atopic dermatitis (AD), by pursuing an integrative multi-omics approach. As a consequence of the heterogeneity among IMIDs patients, a comprehensive, evidence-based identification of novel biomarkers is necessary to enable appropriate patient stratification that would account for the inter-individual differences in disease severity, drug efficacy, side effects or prognosis. This would guide clinicians in the management of patients and represent a major step towards personalized medicine. ImmUniverse will combine the existing and novel advanced technologies, including multi-omics, to characterize both the tissue microenvironment and blood. This comprehensive, systems biology-oriented approach will allow for identification and validation of tissue and circulating biomarker signatures as well as mechanistic principles, which will provide information about disease severity and future disease progression. This truly makes the ImmUniverse Consortium an unparalleled approach.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682955PMC
http://dx.doi.org/10.3389/fimmu.2022.1002629DOI Listing

Publication Analysis

Top Keywords

immuniverse consortium
8
personalized medicine
8
inflammatory diseases
8
atopic dermatitis
8
disease progression
8
disease severity
8
disease
6
immuniverse
5
will
5
consortium multi-omics
4

Similar Publications

Article Synopsis
  • More severe forms of atopic dermatitis and psoriasis significantly impact quality of life, lead to higher healthcare costs, and are linked to other health issues; addressing these problems early can help lessen the burden.
  • The BIOMAP consortium is a large-scale research initiative that compiles clinical and molecular data from various studies to improve the understanding of disease severity and identify reliable biomarkers.
  • The consortium emphasizes the importance of using consistent definitions for disease severity and considers various factors when analyzing data to ensure that findings are relevant to both patients and healthcare practitioners.
View Article and Find Full Text PDF

Immune mediated inflammatory diseases (IMIDs) are a heterogeneous group of debilitating, multifactorial and unrelated conditions featured by a dysregulated immune response leading to destructive chronic inflammation. The immune dysregulation can affect various organ systems: gut (e.g.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!

A PHP Error was encountered

Severity: Notice

Message: fwrite(): Write of 34 bytes failed with errno=28 No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 272

Backtrace:

A PHP Error was encountered

Severity: Warning

Message: session_write_close(): Failed to write session data using user defined save handler. (session.save_path: /var/lib/php/sessions)

Filename: Unknown

Line Number: 0

Backtrace: